
    
      Objectives: This goal of this study is to continue treating two patients with Fabry disease
      using enzyme replacement therapy (ERT) using Replagal (agalsidase alfa) at a dose of 0.2
      mg/kg of body weight administered every 2 weeks. Study Population: Two patients with Fabry
      disease who are currently on clinical research protocols 00-N-0185/TKT011 or 02-N-0220/TKT015
      and who are stable on ERT. Design: This is an open label study. Outcome Measures: Mainly
      safety parameters will be obtained. Study duration is estimated to be 2 years.
    
  